Cell-Based Therapy for the Treatment of Glioblastoma: An Update from Preclinical to Clinical Studies

Glioblastoma (GB), an aggressive primary tumor of the central nervous system, represents about 60% of all adult primary brain tumors. It is notorious for its extremely low (~5%) 5-year survival rate which signals the unsatisfactory results of the standard protocol for GB therapy. This issue has beco...

Descripción completa

Detalles Bibliográficos
Autores principales: Attia, Noha, Mashal, Mohamed, Pemminati, Sudhakar, Omole, Adekunle, Edmondson, Carolyn, Jones, Will, Priyadarshini, Priyanka, Mughal, Temoria, Aziz, Pauline, Zenick, Blesing, Perez, Ambar, Lacken, Morgan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750228/
https://www.ncbi.nlm.nih.gov/pubmed/35011678
http://dx.doi.org/10.3390/cells11010116

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750228/
https://www.ncbi.nlm.nih.gov/pubmed/35011678
http://dx.doi.org/10.3390/cells11010116

Ejemplares similares